Table 5 Top 10 significant GWAS-informed gene methylation sites
Sleep Measure | Chr | Position | Gene | Î’1 | (SE) | Q value | Function/Disease in Previous Studies2 | Location |
|---|---|---|---|---|---|---|---|---|
Bedtime (hh:mm) | ||||||||
PSG | chr5 | 92,956,911 | FAM172A | 2.5 | 0.3 | 6.2E-09 | Major Depressive Disorder | Intragenic |
chr7 | 113,727,472 | FOXP2 | 1.3 | 0.2 | 1.6E-07 | Developmental Apraxia | Intragenic | |
chr7 | 1,959,919 | MAD1L1 | 2.2 | 0.3 | 3.8E-06 | Smoking Status, Depression | Intragenic | |
chr17 | 26,926,079 | RSKR | 1.0 | 0.2 | 5.9E-06 | Reticulocyte count | Intragenic | |
chr11 | 61,583,318 | FADS1 | 0.9 | 0.1 | 5.9E-06 | Neoplasms, Hypertension | Intragenic | |
chr11 | 113,931,707 | ZBTB16 | 3.1 | 0.5 | 5.9E-06 | Skeletal Defects, Depression | Intragenic | |
chr5 | 176,882,353 | PRR7 | 3.8 | 0.7 | 2.2E-05 | NMDA receptor-mediated excitotoxicity | Intragenic | |
chr18 | 56,807,389 | SEC11C | 1.1 | 0.2 | 3.6E-05 | Neoplasms | Intragenic | |
chr20 | 62,669,859 | C20orf204 | 1.1 | 0.2 | 3.7E-05 | Neoplasms | Intragenic | |
chr16 | 12,541,889 | SNX29 |  − 0.6 | 0.1 | 1.4E-04 | Intelligence | Intragenic | |
Sleep latency (min) | ||||||||
Self-report | chr14 | 101,034,180 | BEGAIN |  − 113 | 15.1 | 4.8E-08 | Synapse structural protein, platelet count | Intragenic |
chr19 | 5,139,393 | KDM4B |  − 120 | 16.4 | 6.1E-08 | Medulloblastoma | Intragenic | |
chr11 | 66,384,606 | RBM14-RBM4 |  − 154 | 23.9 | 1.4E-06 | Neoplasms | Intragenic | |
chr7 | 4,212,386 | SDK1 | 103 | 16.0 | 1.6E-06 | Anxiety Disorder | Intragenic | |
chr16 | 23,079,460 | USP31 | 108 | 16.9 | 1.6E-06 | Bone mineral density, chronotype | Intragenic | |
chr18 | 31,803,203 | NOL4 |  − 83 | 14.0 | 8.1E-06 | Circadian Rhythms, Narcolepsy | Intragenic | |
chr19 | 2,595,453 | GNG7 | 70 | 11.9 | 1.2E-05 | Neoplasms | Intragenic | |
chr2 | 236,963,701 | AGAP1 | 57 | 10.3 | 4.2E-05 | Autism | Intragenic | |
chr11 | 122,103,506 | MIR100HG | 86 | 15.8 | 5.7E-05 | BMI, Intellectual ability | Intragenic | |
chr4 | 148,710,543 | ARHGAP10 | 124 | 26.3 | 1.5E-03 | Atrial Fibrillation | Intragenic | |
ACT | chr2 | 178,937,545 | PDE11A |  − 244 | 37.4 | 1.1E-05 | Adrenocortical Disease, Depression | Intragenic |
chr16 | 12,070,441 | SNX29 |  − 481 | 77.9 | 2.4E-05 | Intelligence | Upstream | |
chr16 | 56,225,673 | GNAO1 |  − 235 | 43.7 | 4.7E-04 | Seizure Disorders | Intragenic | |
chr11 | 13,298,902 | ARNTL |  − 242 | 46.2 | 6.4E-04 | Bipolar Disorder | Upstream | |
chr5 | 58,335,105 | PDE4D |  − 700 | 136.9 | 7.0E-04 | Mental Depression | Intragenic | |
chr11 | 33,757,983 | CD59 |  − 432 | 85.9 | 7.7E-04 | Complement Inhibitor | Intragenic | |
chr6 | 13,201,100 | PHACTR1 |  − 52 | 11.3 | 2.8E-03 | Epilepsy, Coronary Artery Disease | Intragenic | |
chr4 | 83,295,543 | HNRNPD |  − 463 | 104.5 | 5.4E-03 | Neoplasms | Downstream | |
chr5 | 80,256,552 | RASGRF2 |  − 75 | 17.2 | 8.5E-03 | Neoplasms | Intragenic | |
chr10 | 72,989,362 | UNC5B | 19 | 4.6 | 2.7E-02 | Subarachnoid Hemorrhage | Intragenic | |
PSG | chr4 | 114,682,603 | CAMK2D |  − 728 | 133.4 | 7.2E-04 | Atrial Fibrillation | Intragenic |
chr11 | 33,757,983 | CD59 |  − 1293 | 240.6 | 7.2E-04 | Complement Inhibitor | Intragenic | |
chr17 | 17,399,610 | RASD1 |  − 995 | 189.1 | 7.2E-04 | Neoplasms, Circadian Rhythms | Intragenic | |
chr12 | 6,875,771 | MLF2 |  − 651 | 129.0 | 1.6E-03 | Colorectal Carcinoma | Intragenic | |
chr17 | 2,240,898 | SGSM2 |  − 7783 | 1574.7 | 1.7E-03 | Insulin Measurement | Intragenic | |
chr5 | 176,882,488 | PRR7 |  − 1812 | 367.0 | 1.7E-03 | NMDA receptor-mediated excitotoxicity | Intragenic | |
chr7 | 21,582,642 | DNAH11 |  − 2132 | 438.2 | 2.0E-03 | Ciliary Dyskinesia | Upstream | |
chr11 | 61,583,308 | FADS1 |  − 834 | 196.3 | 2.0E-02 | Neoplasms, Hypertension | Intragenic | |
chr3 | 47,018,027 | CCDC12 |  − 1551 | 367.1 | 2.0E-02 | Leukocyte count, Waist-Hip Ratio | Intragenic | |
chr15 | 66,691,039 | MAP2K1 | 180 | 45.3 | 4.6E-02 | Cardio-facio-cutaneous syndrome, MDD | Intragenic | |